✦ LIBER ✦

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

✍ Scribed by Decramer, Marc L; Chapman, Kenneth R; Dahl, Ronald; Frith, Peter; Devouassoux, Gilles; Fritscher, Carlos; Cameron, Ray; Shoaib, Muhammad; Lawrence, David; Young, David; McBryan, Danny

Book ID: 121198954
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 379 KB
Volume: 1
Category: Article
ISSN: 2213-2600
DOI: 10.1016/S2213-2600(13)70158-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of once-daily QVA149

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

✍ Vogelmeier, Claus F; Bateman, Eric D; Pallante, John; Alagappan, Vijay KT; D'And 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 423 KB

Analysis of chronic obstructive pulmonar

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

✍ Wedzicha, Jadwiga A; Decramer, Marc; Ficker, Joachim H; Niewoehner, Dennis E; Sa 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 345 KB

80* A randomised, double-blind, placebo-

80* A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis

✍ J.S. Elborn; A. Sharma; Q. Deng; P. Koker 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB